Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CDIO - US14159C2026 - Common Stock

1.84 USD
+0.09 (+5.14%)
Last: 1/21/2026, 4:30:02 PM
1.7705 USD
-0.07 (-3.78%)
After Hours: 1/21/2026, 4:30:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CDIO. CDIO was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CDIO as it has an excellent financial health rating, but there are worries on the profitability. CDIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CDIO has reported negative net income.
  • In the past year CDIO has reported a negative cash flow from operations.
  • In the past 5 years CDIO always reported negative net income.
  • In the past 5 years CDIO reported 4 times negative operating cash flow.
CDIO Yearly Net Income VS EBIT VS OCF VS FCFCDIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

  • CDIO has a worse Return On Assets (-74.52%) than 64.57% of its industry peers.
  • CDIO has a Return On Equity of -80.37%. This is comparable to the rest of the industry: CDIO outperforms 51.81% of its industry peers.
Industry RankSector Rank
ROA -74.52%
ROE -80.37%
ROIC N/A
ROA(3y)-112.88%
ROA(5y)-106.11%
ROE(3y)-159.71%
ROE(5y)-310.75%
ROIC(3y)N/A
ROIC(5y)N/A
CDIO Yearly ROA, ROE, ROICCDIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CDIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDIO Yearly Profit, Operating, Gross MarginsCDIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

7

2. Health

2.1 Basic Checks

  • CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CDIO has more shares outstanding
  • The debt/assets ratio for CDIO has been reduced compared to a year ago.
CDIO Yearly Shares OutstandingCDIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M
CDIO Yearly Total Debt VS Total AssetsCDIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • CDIO has an Altman-Z score of -3.02. This is a bad value and indicates that CDIO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.02, CDIO perfoms like the industry average, outperforming 46.86% of the companies in the same industry.
  • There is no outstanding debt for CDIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.02
ROIC/WACCN/A
WACC8.72%
CDIO Yearly LT Debt VS Equity VS FCFCDIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 17.32 indicates that CDIO has no problem at all paying its short term obligations.
  • CDIO has a better Current ratio (17.32) than 94.29% of its industry peers.
  • A Quick Ratio of 17.32 indicates that CDIO has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 17.32, CDIO belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.33
Quick Ratio 17.33
CDIO Yearly Current Assets VS Current LiabilitesCDIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.00% over the past year.
  • CDIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.74%.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.35%
Revenue 1Y (TTM)-55.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.93%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • CDIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 2032.01% yearly.
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO Yearly Revenue VS EstimatesCDIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
CDIO Yearly EPS VS EstimatesCDIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • CDIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDIO Price Earnings VS Forward Price EarningsCDIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDIO Per share dataCDIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • CDIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (1/21/2026, 4:30:02 PM)

After market: 1.7705 -0.07 (-3.78%)

1.84

+0.09 (+5.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-18
Inst Owners6.3%
Inst Owner Change0%
Ins Owners3.9%
Ins Owner Change0%
Market Cap3.37M
Revenue(TTM)15.80K
Net Income(TTM)-6.55M
Analysts82.86
Price Target61.2 (3226.09%)
Short Float %0.32%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-94.15%
Min Revenue beat(2)-98.1%
Max Revenue beat(2)-90.2%
Revenue beat(4)1
Avg Revenue beat(4)368.61%
Min Revenue beat(4)-98.1%
Max Revenue beat(4)1743.14%
Revenue beat(8)1
Avg Revenue beat(8)140.1%
Revenue beat(12)1
Avg Revenue beat(12)61.01%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 213.11
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-9.9
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-3.36
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS0.01
BVpS4.45
TBVpS4.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.52%
ROE -80.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-112.88%
ROA(5y)-106.11%
ROE(3y)-159.71%
ROE(5y)-310.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 101.25%
Cap/Sales 2468.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.33
Quick Ratio 17.33
Altman-Z -3.02
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)426.53%
Cap/Depr(5y)425.92%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.35%
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-55.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.93%
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.13%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIO DIAGNOSTICS HOLDINGS / CDIO FAQ

What is the fundamental rating for CDIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to CDIO.


What is the valuation status for CDIO stock?

ChartMill assigns a valuation rating of 0 / 10 to CARDIO DIAGNOSTICS HOLDINGS (CDIO). This can be considered as Overvalued.


How profitable is CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a profitability rating of 0 / 10.


What is the expected EPS growth for CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

The Earnings per Share (EPS) of CARDIO DIAGNOSTICS HOLDINGS (CDIO) is expected to grow by 22.73% in the next year.